Succinic semialdehyde dehydrogenase deficiency: an inborn error of 4-aminobutyric acid metabolism – University of Copenhagen

DRA > Activities > 2018 > Symposier og lectures > Succinic semialdehyde ...

Succinic semialdehyde dehydrogenase deficiency: an inborn error of 4-aminobutyric acid metabolism

DRA lecture held by professor Mike Gibson, Department of Pharmacotherapy, College of Pharmacy, Washington State University, US

Dr. Gibson was the person to originally discover the enzyme involved in succinic semialdehyde dehydrogenase (SSADH) deficiency in 1983. Patients with this deficiency, although rare, experience mental retardation, speech impairment and seizures, likely related to increased levels of GHB and GABA in the brain. Ongoing research in Dr. Gibson’s group is focused on targeted development of medicines to treat the disorder. The majority of the work is performed in mouse models i.e. SSADH knock-out mice, but clinical trials are also undertaken (including three active ongoing trials).

In addition to the description of his research of interest to biochemists, pharmacologists and neuroscientists, Dr. Gibson will give a historical perspective from the first identification of the enzyme of the disorder to clinical trials and the accompanying challenges and experiences for an academic researcher.

The lecture is arranged on behalf of the graduate programme in pharmaceutical sciences, Drug Research Academy, Faculty of Health and Medical Sciences, University of Copenhagen by Petrine Wellendorph,  Department of Drug Design and Pharmacology.

The arrangement is free of charge and open for attendance by all interested parties. It is not necessary to pre-register.